Home/Capricor Therapeutics/Kristi A. H. Elliott, Ph.D.

KA

Kristi A. H. Elliott, Ph.D.

Chief Operating & Science Officer

Capricor Therapeutics

Therapeutic Areas

Rare Diseases Neuromuscular Cardiology Infectious Disease

Capricor Therapeutics Pipeline

Drug	Indication	Phase
Deramiocel (CAP-1002)	Duchenne Muscular Dystrophy (DMD)	Phase 3
StealthX™ Vaccine	COVID-19 (Booster)	Phase 1
StealthX™ Therapeutics	Oncology & Other Targets	Preclinical

Leadership Team at Capricor Therapeutics

Linda Marbán, Ph.D.

Chief Executive Officer and Director

Frank Litvack, M.D., FACC

Executive Chairman

Michael Binks, M.D.

Chief Medical Officer

View full Capricor Therapeutics profile